Betaine

Betaine (Trimethylglycine): A Comprehensive Reference

1. Identity and Chemical Character

Betaine (trimethylglycine, glycine betaine, lycine, or oxyneurine) is a zwitterionic quaternary ammonium compound, discovered in the nineteenth century in the juice of sugar beets. It is also called trimethylglycine because it looks like a glycine with three extra methyl groups, and it carries the zwitterionic quaternary ammonium form [(CH₃)₃N⁺CH₂COO⁻].

Trimethylglycine is an amino acid derivative with the formula (CH₃)₃N⁺CH₂CO₂⁻. A colorless, water-soluble solid, it occurs in plants. Trimethylglycine is a zwitterion: the molecule contains both a quaternary ammonium group and a carboxylate group. The chemical name of betaine anhydrous is trimethylglycine, with a molecular weight of 117.15.

In the broader chemical sense, "a betaine" refers to any neutral chemical compound with a positively charged cationic functional group bearing no hydrogen atom—such as a quaternary ammonium cation—and a negatively charged functional group such as a carboxylate group. They are zwitterions but cannot isomerize because there is no labile hydrogen attached to the nitrogen. Historically, the term was reserved for trimethylglycine (TMG), which is involved in methylation reactions and detoxification of homocysteine.

Betaine is a heat-stable compound. The critical decomposition temperature of pure anhydrous betaine is up to 245°C. Betaine is a highly polar compound (log P = −4.49), fully soluble in water and in methanol. Betaine anhydrous powder is very soluble in water, soluble in methanol and ethanol, and sparingly soluble in ether.

The pronunciation of the compound reflects its origin and first isolation from sugar beets (Beta vulgaris subsp. vulgaris), and does not derive from the Greek letter beta (β). It is commonly pronounced beta-INE or BEE-tayn.

2. Natural Sources and Dietary Occurrence

Betaine was first discovered in the juice of sugar beets (Beta vulgaris) in the 19th century and was subsequently found in several other organisms. It was then found at high concentrations in several other organisms, including wheat bran, wheat germ, spinach, beets, microorganisms, and aquatic invertebrates. It is worth mentioning that betaine is also the main water-soluble component of traditional Chinese medicine Lycium barbarum.

Whole grain wheat and related fractions are the best overall common source of betaine in Western diets, while the pseudocereal quinoa has the highest amount of betaine measured among commonly consumed foods; cereal foods, and not spinach, are the major source of betaine in Western diets. Cereal foods provide approximately 60–67% of betaine in Western diets, and 20–40% of betaine in South-East Asian diets.

Quantitative data from authoritative analysis indicate the following concentrations: the foods with the highest betaine concentration (mg/100 g) are wheat bran (1,506), wheat germ (1,395), spinach (725), pretzels (266), shrimp (246), and wheat bread (227). According to EFSA data, betaine content is highest in quinoa (630 mg/100 g), followed by ready-to-eat breakfast cereals (up to 360 mg/100 g), beets and spinach (120 mg/100 g), wheat bread (85 mg/100 g), spaghetti (68 mg/100 g), snacks (50 mg/100 g), and white bread and chicken (30 mg/100 g). Meats, poultry, fruits, nuts, and wine are generally not good sources of betaine (less than 6 mg/100 g).

It has been established that the bran and germ fraction of wheat are the most abundant sources of betaine, and that whole-grain-based products can contain 2–3 times more betaine than refined products. The pseudocereals amaranth and quinoa appear to be among the richest sources of betaine: amaranth contains 7.4 mg/g of betaine and quinoa contains approximately 3.9 mg/g.

Sugar beet molasses, a by-product of beet sugar production, is also a concentrated source of betaine; with average betaine contents in the range of 5–6 g/100 g, it represents an excellent source of betaine.

Regarding typical dietary intake, average daily intakes of betaine range from 100 to 300 mg/day. Some estimates put the daily dietary intake of betaine at approximately 1 to 2.5 g, with foods such as wheat and shellfish being particularly rich sources.

3. Biosynthesis and Endogenous Metabolism

In addition to being taken in through the diet, betaine can also be synthesized in mitochondria through a two-step oxidation reaction from choline. For human beings, betaine is an important nutrient which is synthesized through the choline metabolic pathway and mainly exists in the human liver and kidney.

Betaine is closely related to choline. The difference is that choline (tetramethylglycine) has four methyl groups attached to it. When choline donates one of these groups to another molecule, it becomes betaine (trimethylglycine). If betaine donates one of its methyl groups, it becomes dimethylglycine.

Either ingested as a dietary supplement or from food, betaine has similar bioavailability, being broken down to dimethylglycine and lastly to sarcosine in the mitochondria of kidney and liver cells.

Betaine is also synthesized in the liver by the oxidation of dietary choline, and common causes of betaine deficiency are often related to malnutrition from conditions such as chronic alcoholism.

4. Common Forms and Preparations

Betaine is commercially available in several distinct forms that serve different purposes:

• Betaine anhydrous (trimethylglycine, TMG): Cystadane is a white, granular, hygroscopic powder for oral solution. This is the pharmaceutical-grade form approved for the treatment of homocystinuria and the form most commonly used in dietary supplements intended to support methylation and homocysteine metabolism.
• Betaine monohydrate: The chemical formula of the anhydrous form of betaine is (CH₃)₃N⁺CH₂COO⁻ (molecular mass 117.15 Da), whereas for the monohydrate form it is (CH₃)₃N⁺CH₂COO⁻·H₂O (molecular mass 135.16 Da).
• Betaine hydrochloride (betaine HCl): Betaine is most widely available as betaine hydrochloride, but that form is used primarily as a source of hydrochloric acid for people with hypochlorhydria (low stomach acid). Betaine hydrochloride was sold over-the-counter (OTC) as a purported gastric aid in the United States; however, US Code of Federal Regulations, Title 21, Section 310.540, which became effective in November 1993, banned the marketing of betaine hydrochloride as a digestive aid due to insufficient evidence to classify it as "generally recognized as safe and effective" for that specified use.
• Betaine citrate and betaine aspartate: The forms used specifically to provide betaine as a supplement are betaine citrate and betaine aspartate, which have also been used to improve liver function.

The compound is placed on the market under different brand names including, as anhydrous betaine: Betafin™ BF20, Natural Extract BF, and BetaPower™; and as monohydrate betaine: Betafin™ AF20 and Natural Extract AF.

In the United States of America, betaine is generally recognized as a safe (GRAS) ingredient, while in Europe it has approval for use in food from the European Commission, which allows the safe use of betaine in food in an amount of at least 500 mg per food serving.

5. Historical Discovery and Traditional Context

Trimethylglycine, originally coined and referred to as betaine, was discovered in the early 19th century in sugar beets. Early characterization revealed its zwitterionic nature, and by the late 19th century, it was understood as a derivative of glycine with three methyl groups attached to the nitrogen atom, leading to its alternative designation as trimethylglycine. Initial industrial isolation methods focused on sugar beet molasses, exploiting the low solubility of betaine hydrochloride in concentrated hydrochloric acid to precipitate and recover the compound from crude extracts, a technique that laid the foundation for its commercial production as a by-product of beet sugar refining.

Betaine's function in mammalian systems, particularly in one-carbon metabolism where it serves as a key methyl donor for converting homocysteine to methionine via the enzyme betaine-homocysteine S-methyltransferase, was first elucidated in the 1940s, with further research expanding on this in subsequent decades including the 1980s.

It is important to note that betaine does not feature prominently in the classical herbal medicine traditions (such as Ayurveda, traditional European herbalism, or Chinese medicine) as an isolated therapeutic agent. Its historical use prior to the 20th century was primarily culinary — as part of beet consumption and whole-grain cereal diets — rather than as a deliberately extracted or administered remedy. Traditionally, betaine recovered from beet molasses was used as a liquid animal feed supplement. In traditional Chinese medicine, however, Lycium barbarum (wolfberry/goji berry) is a well-established botanical in which betaine is the main water-soluble component, though historical practitioners identified and used the whole fruit rather than betaine as an isolated compound.

The systematic scientific and clinical study of betaine as a distinct nutritional and pharmacological agent is largely a product of the 20th and 21st centuries, driven by the expansion of the sugar beet industry and the emergence of nutritional biochemistry as a discipline.

6. Key Constituents, Active Compounds, and Mechanisms of Action

Betaine itself is the single bioactive molecule of interest in this context. Its physiological actions arise from three well-characterized functional roles:

6.1 Methyl Group Donation (Transmethylation)

A cytosolic methyltransferase enzyme, betaine-homocysteine S-methyltransferase (BHMT), uses betaine as the methyl donor for the remethylation of homocysteine. Betaine plays three major roles in the mammalian organism: firstly, as an organic osmolyte, it maintains normal cell volume under osmotic stress; secondly, it provides protection against protein denaturation; and thirdly, besides methylfolate, betaine is the only molecule that provides methyl groups for homocysteine remethylation.

Betaine acts as a methyl donor in the methionine cycle by donating a methyl group to homocysteine via betaine-homocysteine methyltransferase, leading to the formation of methionine and supporting the synthesis of S-adenosylmethionine (SAM), a central methyl donor in cellular metabolism. The increased availability of SAM, in turn, stimulates the synthesis of key biological compounds, such as creatine and carnitine.

Methyl groups are important for numerous cellular functions such as DNA methylation, phosphatidylcholine synthesis, and protein synthesis. The methyl group can be directly delivered by dietary methyl donors, including methionine, folate, betaine, and choline. The liver and the muscles appear to be the major organs for methyl group metabolism.

BHMT is an enzyme that catalyzes the remethylation of homocysteine to methionine with betaine as the methyl donor. Methionine is then converted to SAM, the key methyl donor required for histone and DNA methylation.

6.2 Osmoprotection (Osmolyte Function)

Betaine is stored in the kidney and liver, and serves three important physiological functions: it acts as an osmolyte that regulates cell volume, it acts as a chemical chaperone that protects against protein degradation, and it serves as a methyl donor in the methionine cycle which detoxifies homocysteine to methionine — a process that is crucial for numerous cellular functions.

Betaine's osmolytic action is the result of a dipolar structure and good solubility in water; along with other organic osmolytes, it demonstrates a lower degree of interaction with enzyme functions and metabolic processes in cells. Studies have shown that betaine has a very low potential to bind to the protein surface, thereby allowing cells to control the water surface tension without affecting lipase stabilization.

The physiological function of betaine is either as an organic osmolyte to protect cells under stress or as a catabolic source of methyl groups via transmethylation. The principal role for betaine in plants and microorganisms is to protect cells against osmotic inactivation. Exposure to drought, high salinity, or temperature stress triggers betaine synthesis in mitochondria, which results in its accumulation in the cells.

6.3 Protein Stabilization (Chemical Chaperone Activity)

Betaine protects proteins from urea-induced denaturation by preventing the formation of folding intermediates that promote the loss of enzymatic structure and function. Moreover, as an osmolyte, betaine has been demonstrated to enhance water structure and promote tighter protein folding, which may further contribute to its stabilizing effects on protein conformation.

6.4 Epigenetic Regulation

Hypomethylation has a wide spectrum of effects that include genetic, epigenetic, and metabolic alterations. Dietary methyl donors or endogenously produced methyl groups are promising for disease prevention and risk modification. S-adenosylmethionine (SAM) is the major methyl donor in the cell. It is involved in numerous cellular reactions, including DNA methylation and synthesis of phosphatidylcholine, and in reactions involving neurotransmitters, creatine, carnitine, and antioxidants such as glutathione and taurine.

Research has demonstrated that the methyl donor betaine is depleted in multiple sclerosis and is linked to changes in histone H3 trimethylation (H3K4me3) in neurons; betaine also increases histone methyltransferase activity by activating chromatin-bound BHMT.

6.5 Antioxidant Activity

The ability of betaine to scavenge reactive oxygen species (ROS) has not been determined by classical chemical assays such as the ferric-reducing antioxidant power (FRAP) test. On the other hand, betaine's antioxidant activity has been determined in animal and plant models, suggesting that the interaction of betaine with the organism could be essential for its redox activity.

Acting as both an osmolyte and a methyl group donor, betaine contributes to cellular hydration, methylation balance, antioxidant defense, and metabolic regulation.

7. Scientific Evidence by Health Area

7.1 Homocysteine Metabolism and Cardiovascular Risk Markers

This is the most thoroughly studied and most clinically robust application of betaine supplementation.

A meta-analysis of five clinical trials shows that betaine supplementation of 4 to 6 g/d significantly lowers plasma homocysteine concentration in healthy adults by 1.23 μmol/L, or approximately 11.8% of baseline. Betaine appears to be highly effective in preventing a rise in plasma homocysteine concentration after methionine intake in subjects with mildly elevated homocysteine.

An inverse association between dietary betaine intakes and homocysteine concentrations has been observed in the sixth examination of the Framingham Offspring Study. Low plasma betaine concentrations have been shown to be related to an unfavorable cardiovascular risk profile and an increased risk of secondary heart failure and acute myocardial infarction.

However, a critical limitation is that homocysteine lowering does not automatically translate into reduced cardiovascular events. Although several studies have found an association between elevated homocysteine levels and cardiovascular risk, evidence from randomized controlled trials using supplements to lower homocysteine has not consistently shown a reduction in cardiovascular events. Clinical trials consistently lowered homocysteine levels using supplemental folate, vitamin B6, and vitamin B12; however, meta-analyses show no impact on risk of cardiovascular events including myocardial infarction and death, though findings are mixed for stroke. In light of cumulative evidence, it is increasingly recognized that homocysteine functions more reliably as a marker of cardiovascular risk rather than a modifiable therapeutic target in patients with established vascular disease.

An important safety concern that offsets cardiovascular benefits is betaine's effect on lipids: betaine supplementation increased blood LDL cholesterol and triacylglycerol concentrations in healthy humans; the adverse effects on blood lipids may undo the potential benefits for cardiovascular health of betaine supplementation through homocysteine lowering. Specifically, a significant increase in total and LDL-cholesterol concentrations was noted at intakes of 4 g/day of betaine in overweight subjects with metabolic syndrome, but not in healthy subjects, nor at intakes of 3 g/day.

Overall evidence strength: Moderate-to-strong for homocysteine lowering as a biochemical endpoint; weak-to-insufficient for clinically relevant cardiovascular outcomes such as myocardial infarction or stroke. The lipid-raising effect at higher doses complicates the cardiovascular risk-benefit picture.

7.2 Homocystinuria (Pharmaceutical Indication)

This is the only indication for which betaine carries a formal regulatory approval.

The US Food and Drug Administration (FDA) approved betaine trimethylglycine (also known by the brand name Cystadane) for the treatment of homocystinuria, a disease caused by abnormally high homocysteine levels. Specifically, the compound is indicated for the adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylene-tetrahydrofolate reductase (MTHFR), or cobalamin cofactor metabolism.

Betaine (trimethylglycine), typically in doses of 4 g/day or more, is a cornerstone therapy for certain types of homocystinuria and MTHFR deficiencies, acting as an alternative methyl donor.

When administered in recommended oral dosage to children or adults, Cystadane acts as a methyl group donor in the remethylation of homocysteine to methionine in patients with homocystinuria. Plasma levels of homocysteine were decreased in nearly all patients treated with betaine.

Overall evidence strength: Strong and confirmed; this is an FDA-approved indication supported by consistent clinical evidence across multiple patient series.

7.3 Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, has been proposed as a therapeutic agent for non-alcoholic steatohepatitis (NASH).

The most rigorous human trial conducted to date yielded mixed results. A randomized placebo-controlled study enrolled 55 patients with biopsy-proven NASH who received either oral betaine (20 g daily) or placebo for 12 months; pre- and post-treatment variables were analyzed, and treatment groups were comparable at baseline. Of the 35 patients who completed the study (17 betaine, 18 placebo), 34 underwent post-treatment liver biopsy. Although betaine improved hepatic steatosis and may protect against worsening steatosis compared to placebo, high-dose betaine supplementation failed to reduce S-adenosylhomocysteine and did not positively affect any of the second-hit mechanisms postulated to contribute to NASH.

In a cross-sectional study, a significant inverse association was observed between the plasma betaine concentration and the severity of NAFLD in 1,628 community-based participants.

Although betaine was evaluated for NASH, results were mixed in the clinical trials in large part due to the quality of the studies. Although betaine has been proven effective in treating hepatic steatosis in several animal models, translating novel therapeutic options noted in animal studies to humans with NASH has proven challenging.

Overall evidence strength: Preliminary and mixed. Preclinical evidence is compelling, but human trials have been hampered by small sample sizes, high dropout rates, and heterogeneous populations. Current evidence does not support betaine as an established treatment for NASH.

7.4 Alcoholic Liver Disease

Betaine's role in preventing and attenuating alcohol-induced liver disease has been well studied. Several studies show that betaine protects against the development of alcohol-induced hepatic steatosis, apoptosis, and accumulation of damaged proteins. The mechanism centers on betaine's ability to restore hepatic SAM levels depleted by alcohol metabolism, thereby normalizing transmethylation reactions in the liver.

Overall evidence strength: Preclinical evidence (animal models) is robust; direct, high-quality human clinical trial evidence for alcoholic liver disease remains limited.

7.5 Exercise Performance and Athletic Ergogenics

Betaine, also known as trimethylglycine, is found in foods such as beets, spinach, and whole-grain breads. The mechanisms by which betaine might enhance exercise and athletic performance are not fully known, but many are hypothesized. For example, betaine might increase the biosynthesis of creatine, levels of blood nitric oxide, and/or the water retention of cells.

Betaine has been hypothesized to mitigate fatigue by increasing the availability of free choline via its proposed role as a methyl donor in phosphatidylcholine synthesis, thereby potentially supporting acetylcholine production in motor neurons. Enhanced acetylcholine synthesis may sustain the central drive, facilitate continuous motor recruitment, and thereby maintain power output.

From seven clinical trials reviewed in one systematic analysis, only two showed an increase in power and strength of muscle after betaine supplementation despite the claimed ergogenic effect and its widespread inclusion as an ingredient in peri-workout dietary supplements.

The interpretation of findings is further limited by the substantial variability in population characteristics, dosing protocols, assessment methods, and the consistently high risk of bias across all studies. Nonetheless, exploratory findings related to central drive and fatigue perception present a promising avenue for future research, suggesting that betaine may confer benefits in endurance sports involving intermittent bursts of explosive movements; however, these potential effects require further investigation.

More research on betaine supplementation to enhance various types of performance, training protocols, and exercise during specific sports is needed before any recommendations for its use can be made.

Overall evidence strength: Weak-to-preliminary. The existing trials are small, predominantly conducted in men, and show inconsistent results. The body of evidence does not yet support firm conclusions about betaine as an ergogenic aid.

7.6 Body Composition

Several clinical studies have investigated betaine's potential role in modifying body composition, particularly in reducing fat mass and preserving lean mass. The proposed mechanism involves betaine's role as a methyl donor influencing lipid metabolism and its osmolyte function in muscle cell hydration. However, results across trials have been mixed, and the evidence base mirrors the limitations seen in the exercise performance literature: small samples, variable protocols, and high risk of bias. This area is considered preliminary.

7.7 Inflammation

Betaine supplementation has been shown to reduce inflammatory markers and improve glycemic control, insulin resistance, renal function, liver injury, adipose dysfunction, and intestinal barrier integrity in relevant models. Supplementation with betaine and foods rich in betaine have been related to anti-inflammatory activity in diseases such as diabetes, non-alcoholic fatty liver, and cancer. However, the majority of this evidence derives from animal studies and cell-culture models; well-powered human clinical trials specifically targeting inflammatory outcomes remain limited.

7.8 Epigenetic and Neurological Research

Increased reactive nitrogen species inhibit methionine synthase (MTR) enzymatic activity, causing levels of betaine and S-adenosylmethionine (SAM) to decrease in MS cortical tissue, leading to subsequent changes in methylation and gene transcription. Betaine-homocysteine S-methyltransferase (BHMT) is an enzyme in the methionine cycle that was previously thought to be restricted to the cytoplasm of hepatocytes and kidney cells but has recently been implicated in MS pathology in the brain. Research in this area is currently at the preclinical and mechanistic stage; no clinical trials in neurological conditions have yet generated sufficiently robust results to draw firm conclusions.

General attention on betaine in the last decade has increased greatly due to its involvement in various diseases and pathologies such as obesity, diabetes, vascular diseases, fatty liver conversion due to alcohol consumption, homocystinuria, hyperhomocysteinemia, Alzheimer's disease, obesity, schizophrenia, autism, and cancer, mainly due to its methyl donor and antioxidant properties. All of these associations are currently investigational and require further clinical evidence.

8. Body Systems Associated with Betaine

In humans, betaine supports hepatic function, cardiovascular health, renal protection, and physical performance, mainly by modulating homocysteine metabolism, lipid profiles, and oxidative stress. Summarizing the primary systems involved:

• Hepatic system: Betaine supports liver methylation reactions, protects against fatty infiltration, and is involved in the metabolism of lipids within hepatocytes. Its role in alcohol-induced and metabolic liver disease has been studied most extensively.
• Cardiovascular system: Betaine lowers circulating homocysteine, an established biomarker associated with cardiovascular risk, though direct reduction of cardiovascular events has not been demonstrated in clinical trials.
• Renal system: The osmoregulatory function of betaine assists in protecting renal cells from osmotic stress and electrolyte imbalances.
• Musculoskeletal system: Betaine is investigated as an ergogenic aid affecting muscle strength, power, and body composition, with inconclusive human evidence to date.
• Nervous system: Via its role as a methyl donor supporting SAM synthesis, betaine participates in pathways relevant to neurotransmitter production and epigenetic regulation of gene expression in neural tissue.
• Metabolic and endocrine system: Betaine's influence on one-carbon metabolism and its osmoprotective properties intersect with insulin signaling, lipid metabolism, and glucose homeostasis.

9. Dosage Forms and Doses Reported in Studies

Betaine is administered almost exclusively by the oral route in both pharmaceutical and supplement contexts. The specific doses reported in clinical and regulatory sources are as follows:

• Homocystinuria (pharmaceutical use — Cystadane): The usual dosage used in adult and pediatric patients is 6 grams per day administered orally in divided doses of 3 grams two times per day. Dosages of up to 20 grams per day have been necessary to control homocysteine levels in some patients. In pediatric patients less than 3 years of age, dosage may be started at 100 mg/kg/day divided in twice-daily doses, and then increased weekly by 50 mg/kg increments.
• Homocysteine lowering (supplement use, clinical trials): A meta-analysis of five clinical trials assessed betaine supplementation at 4 to 6 g/day, which significantly lowered plasma homocysteine by approximately 11.8% of baseline. Studies compared groups that ingested 1.5 g/day, 3 g/day, or 6 g/day of betaine over 2 to 6 weeks.
• NASH (clinical trial): A randomized placebo-controlled study enrolled patients with biopsy-proven NASH who received oral betaine 20 g daily for 12 months.
• NAFLD (ongoing study): In a prospective randomized study, patients were prescribed 4 g of betaine per day, with some participants titrated to 8 g per day after 4 weeks.
• Athletic/ergogenic use: Betaine anhydrous has most often been used by adults in doses of 1.25 to 3 grams by mouth twice daily in the supplement context.
• EFSA safety reference: Considering 4 g/day of betaine as a reference point and applying an uncertainty factor of 10 to account for interindividual variability, EFSA considers an amount of 400 mg/day of betaine (6 mg/kg body weight per day for adults) as safe in addition to background dietary exposure. The panel considers the novel food to be safe at a maximum intake of 6 mg/kg bw per day in the target population.

10. Safety Considerations and Interactions

10.1 General Tolerability

Adverse reactions to betaine have been minimal. Several small studies of athletes who took betaine supplements for up to several weeks found no side effects or safety concerns; however, research has not adequately evaluated the long-term safety of betaine in this population.

10.2 Hypermethioninemia and Cerebral Edema

The most serious documented adverse effect is specific to patients with CBS-deficiency homocystinuria treated with high-dose betaine. Patients with homocystinuria due to CBS deficiency may also have elevated plasma methionine concentrations. Treatment with Cystadane may further increase methionine concentrations due to the remethylation of homocysteine to methionine. Cerebral edema has been reported in patients with hypermethioninemia, including patients treated with Cystadane. Plasma methionine concentrations should be monitored in patients with CBS deficiency and should be kept below 1,000 µmol/L through dietary modification and, if necessary, a reduction of Cystadane dose.

10.3 LDL Cholesterol and Triglyceride Elevation

Doses of betaine lower than 6 g/d also raised LDL cholesterol, though these changes were not statistically significant at lower doses. The effect of betaine on LDL cholesterol was already evident after 2 weeks of intervention. The most common side effect in medical applications is elevated blood methionine levels. Trimethylglycine supplementation lowers homocysteine but also raises LDL-cholesterol (given in high doses of 6 g/day) in obese individuals. This lipid-raising effect is a clinically important consideration for individuals using betaine long-term for cardiovascular reasons.

10.4 Elevated Blood Methionine

The most common side effect reported in medical applications is elevated blood methionine levels. This occurs because betaine donates a methyl group to homocysteine, converting it to methionine; at high supplemental doses, methionine can accumulate, particularly in patients whose downstream methionine processing is impaired.

10.5 Regulatory Status and Differentiation from Betaine HCl

A specific betaine anhydrous prescription product (Cystadane) is FDA-approved for the treatment of high urine levels of homocysteine (homocystinuria). Betaine anhydrous should not be confused with betaine hydrochloride — these are not the same preparation.

10.6 Pregnancy and Lactation

There are no data on the presence of betaine in human or animal milk, the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Cystadane and any potential adverse effects on the breastfed child from the drug or the underlying maternal condition.

10.7 Pediatric Use

The safety and effectiveness of Cystadane have been established in pediatric patients. The majority of case studies of homocystinuria patients treated with Cystadane have been pediatric patients, including patients ranging in age from 24 days to 17 years. Children younger than 3 years of age may benefit from dose titration.

10.8 Drug Interactions

Betaine (trimethylglycine) functions very closely with choline, folic acid, vitamin B12, and a form of the amino acid methionine known as S-adenosylmethionine (SAMe). All of these compounds function as "methyl donors." Because betaine operates within the same one-carbon metabolic network as these compounds, the theoretical for additive or competing effects exists, though specific drug-drug interaction data are limited. Formal interaction studies are lacking, and specific contraindicated combinations have not been established in the published literature beyond the precautions related to methionine accumulation in CBS-deficiency.

10.9 Non-essential Status

Betaine is not an essential nutrient, and thus no recognized deficiency state exists.

References

• NIH Office of Dietary Supplements – Dietary Supplements for Exercise and Athletic Performance (Health Professional Fact Sheet)
• Buonaiuto G et al. (2025). Betaine Dietary Supplementation: Healthy Aspects in Human and Animal Nutrition. Antioxidants, 14(7):771. PMC12291949
• Majdalawieh AF et al. (2023). Betaine as a Functional Ingredient: Metabolism, Health-Promoting Attributes, Food Sources, Applications and Analysis Methods. Molecules. PMC10302777
• Zhao G et al. (2018). Betaine in Inflammation: Mechanistic Aspects and Applications. Frontiers in Immunology. PMC5976740
• Olthof MR & Verhoef P. (2013). Betaine supplementation decreases plasma homocysteine in healthy adult participants: a meta-analysis. Nutrition Reviews. PMC3610948
• Djoussé L et al. (2014). Plasma homocysteine, dietary B vitamins, betaine, and choline and risk of peripheral artery disease. Atherosclerosis. PMC4102310
• Olthof MR et al. (2005). Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans. PLoS Medicine. PMID 15916468
• Abdelmalek MF et al. (2009). Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology. PMID 19824078
• Shearer J & Bhatt DL. (2020). Role of betaine in liver disease — worth revisiting or has the die been cast? World Journal of Gastroenterology. PMC7579752
• Solis MY et al. (2025). Effects of betaine supplementation on endurance exercise performance: a systematic review. PMC12325877
• Homocysteine in the Cardiovascular Setting: What to Know, What to Do, and What Not to Do. (2025). PMC12564181
• FDA Approved Labeling – Cystadane (betaine anhydrous for oral solution). U.S. Food and Drug Administration.
• DailyMed – Cystadane (betaine anhydrous for oral solution). U.S. National Library of Medicine.
• EFSA Panel on Dietetic Products, Nutrition and Allergies. (2017). Safety of betaine as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal.
• Craig SAS. (2004). Betaine in human nutrition. American Journal of Clinical Nutrition. ScienceDirect.
• Ross AB et al. (2014). Cereal foods are the major source of betaine in the Western diet. Food Chemistry. ScienceDirect.
• USDA Agricultural Research Service. (2004). Betaine Concentration of Common Foods in the US.
• Obeid R. (2013). The Metabolic Burden of Methyl Donor Deficiency with Focus on the Betaine Homocysteine Methyltransferase Pathway. Nutrients. PMC3798916
• Ganz AB et al. (2021). The BHMT-betaine methylation pathway epigenetically modulates oligodendrocyte maturation. PLOS ONE. PMC8112889
• Montone CMF et al. (2017). New approaches for extraction and determination of betaine from Beta vulgaris samples. Analytical and Bioanalytical Chemistry. PMC5534198
• Arumugam MK et al. (2021). Beneficial Effects of Betaine: A Comprehensive Review. Biology. MDPI.
• Current Status and Future Perspectives of Betaine and Betaine-Based Natural Deep Eutectic Solvents: A Review. (2025). PMC12692387